Marcia Belvin Sells 19,512 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) SVP Marcia Belvin sold 19,512 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total value of $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares of the company’s stock, valued at $149,181.60. The trade was a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

CytomX Therapeutics Stock Up 0.1 %

CTMX opened at $0.67 on Friday. The business has a 50 day moving average price of $0.76 and a two-hundred day moving average price of $0.98. The company has a market cap of $53.41 million, a PE ratio of 3.92 and a beta of 1.05. CytomX Therapeutics, Inc. has a 52 week low of $0.56 and a 52 week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.45. The firm had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. As a group, sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CTMX has been the subject of several research reports. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of CytomX Therapeutics in a report on Friday, March 7th. Finally, StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, CytomX Therapeutics has an average rating of “Moderate Buy” and an average target price of $5.02.

Institutional Trading of CytomX Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of CytomX Therapeutics by 10.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock worth $331,000 after buying an additional 26,373 shares in the last quarter. FMR LLC raised its stake in shares of CytomX Therapeutics by 17.3% during the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock worth $335,000 after buying an additional 41,949 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of CytomX Therapeutics by 1.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 16,359 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after buying an additional 34,032 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of CytomX Therapeutics during the 3rd quarter worth approximately $104,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.